Home / Conditions / Nasal Valve Collapse
Nasal Valve Collapse: when insurers say no, reviewers often say yes
In 24 published external-review decisions involving nasal valve collapse, independent physician reviewers overturned the insurer’s denial 41.7% of the time.
Published decisions
24
2001–2026
Overturned
41.7%
10 denials reversed
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 15 | 20% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 9 | 77.8% |
Typical time to a decision
20 days
Most land between 10 and 21 days
Handled as urgent
8.3%
Expedited when a delay would cause harm
Recent direction
Falling
45.5% → 30% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for sinus surgery, repair of nasal vestibular stenosis; nasal/sinus endoscopy, surgical with ethmoidectomy; nasal/sinus endoscopy, surgical, with frontal sinus exploration, including removal of tissue from frontal sinus; nasal sinus endoscopy, surgical with destruction by radiofrequency ablation, posterior nasal nerve with the approved septoplasty and submucous resection inferior turbinate. Nasal valve collapse (NVC) results from structural incompetence of the external nasal valve, internal nasal valve, or both, leading to dynamic obstruction of the nasal vestibule during inspiration.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The enrollee has requested authorization and coverage for sinus surgery for the placement of bilateral Latera absorbable nasal implants. Nasal obstruction is a result of insufficient airflow through the nose, which is a notable symptom in this patient’s clinical setting. A review of current practices indicate there are both surgical and nonsurgical treatments for nasal obstruction. The FDA approved the Latera implant for the correction of nasal obstruction. One randomized control trial showed a statistically significant improvement with symptoms compared to the placebo group. In addition, in long-term follow-up, patients reported good response, and the rate of device extrusion was low.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: The patient requested authorization and coverage for rhinoplasty (septorhinoplasty) along with the approved septoplasty. A study stated that the short-time manipulation of the nasal respiratory flow by changing the resistance is the suction (Bernoulli phenomenon) of the nasal valve in the nasal entrance. The authors indicated that this physiological nasal valve collapse is a protective passive mechanism for the respiratory mucosa of the nose and the subsequent airways, preventing pathologically increased airflow velocities and possible damage due to shear forces. The middle vault, or the nasal valve area, is the most critical region for nasal breathing and small changes to the valve’s cross-sectional area can exponentially increase airflow resistance.
Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for nasal valve repair with subcutaneous/submucosal lateral wall implant(s). Nasal valve collapse (NVC) refers to either dynamic or static narrowing of the nostrils and leads to a sensation of impeded nasal airflow. As NVC is an anatomic obstruction, medical therapy, such as topical medicated nasal sprays, does not play a significant role in its management. The standard management for NVC includes surgical placement of a cartilage graft in the area of narrowing or weakness. Two randomized controlled clinical trials in 2018 and 2019, respectively, established the safety and efficacy of absorbable nasal implants (ANIs) for the treatment of patients with lateral nasal wall (LNW) insufficiency and patients with dynamic NVC.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for nasal valve collapse was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.